Seach Medical Group Ltd (SEMG) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Seach Medical Group Ltd ILS 2.14, price ILS 2.82, upside -24.0%, quality 64 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.
How to read this chart
60‑month range 1.14 ILA – 5.83 ILA · fair‑value band 1.83 ILA – 2.78 ILA · the 2.82 ILA price screens above the 2.14 ILA fair value. Dashed = 300-day average. As of Oct 4, 2026.
Follow Seach Medical Group in your weekly email
Every Wednesday you see whether Seach Medical Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Seach Medical Group Ltd manufactures and sells medicinal cannabis products worldwide. The company provides cannabis oil and medical cannabis inflorescence products. Seach Medical Group Ltd was incorporated in 1987 and is based in Ramat Gan, Israel.
Stock analysis
Seach Medical Group Ltd (SEMG) currently trades at 2.82 ILA, while our model-based Fair Value estimate is 2.14 ILA, 24.0% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 10.44 ILA per share, and 15 of the 26 models we run sit above the 2.82 ILA price.
Bear case: the Multiples group reads lowest at 1.01 ILA, and 11 of the 26 models stay below the price. Evidence for this calculation is low.
Scenario range: 1.83 ILA (bear) to 2.78 ILA (bull), the price of 2.82 ILA sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Seach Medical Group Ltd reported revenue of 157M ILA in FY2025 versus 67.3M ILA in FY2021, a compound +23.6%/yr. Reported net income was 1.5M ILA in FY2025, compounding −26.9%/yr from FY2021.
Key figures
Market cap 93.2M ILA · P/E ratio 14.6 · P/S ratio 0.14 · EPS (TTM) 0.1930 ILA · Dividend yield 6.4% · Net margin 1.0% · Return on equity 5.5% · Return on assets (EBIT) 5.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 10% below its 52-week high and 31% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −24%, SEMG screens richer than that median.
Fair Value models
Bear 1.83 ILAFair Value 2.14 ILABull 2.78 ILA
Price 2.82 ILA · Upside -24.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.0099 ILS per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.84/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−8.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.7%
Start year 2020 (pandemic). Over 10 years: +54.7% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+53.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−23.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−29.6%
Dividend (yield on the price)6.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−29.6% vs −44.3%, picking up
Profit margin 2019 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 9%
Start year 2020 (pandemic)
⚠ Revenue per share shrinking 46.5%/yr over ~10Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−18.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Israel: IMF forecast 2.1% a year to 2030, 1.7% from 2016 to 2025) that is about −19.8% a year for the price.
Compare Seach Medical Group Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 602 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score64 · Top 25%
Fair Value upside−24.0% · Below median
Profitability
Return on equity (TTM)5.5% · Below median
Return on assets7.5% · Top 25%
Net margin (TTM)4.5% · Below median
Operating margin (TTM)16.9% · Above median
Growth and dividend
Revenue growth−7.3% · Below median
Dividend yield (TTM)6.4% · Top 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Seach Medical Group Ltd Fair Value". https://www.fairvalue-calculator.com/stock/SEMG
Frequently asked questions
Is Seach Medical Group Ltd (SEMG) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of 2.14 ILA versus a price of 2.82 ILA, about −24% upside (overvalued).
What is the fair value of SEMG?
Our model-based fair value for Seach Medical Group Ltd is 2.14 ILA (as of Oct 4, 2026), built from audited fundamentals. The current price: 2.82 ILA.
What is the quality score of SEMG?
Seach Medical Group Ltd has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Seach Medical Group Ltd (SEMG)?
Our model-based price target is the fair value of 2.14 ILA (as of Oct 4, 2026) from 26 valuation models. Cautious scenario 1.83 ILA, optimistic scenario 2.78 ILA. It is a calculation from audited fundamentals, not an analyst target.
What is the Seach Medical Group Ltd stock forecast for 2026?
Our models put fair value at 2.14 ILA, about −24% upside versus a price of 2.82 ILA (overvalued). Cautious scenario 1.83 ILA, optimistic scenario 2.78 ILA. The calculation is refreshed regularly with new filings.
What is the revenue of Seach Medical Group Ltd (SEMG)?
Seach Medical Group Ltd reported trailing-twelve-month revenue of about 154M ILS (latest available figure, as of Oct 4, 2026).
Does Seach Medical Group Ltd pay a dividend?
Seach Medical Group Ltd currently shows a dividend yield of about 6.39% relative to its recent price (as of Oct 4, 2026).
What growth is priced into Seach Medical Group Ltd (SEMG)?
For today's price to be fair in a discounted-cash-flow model, Seach Medical Group Ltd would have to grow free cash flow by -18.1 % per year for five years (discount rate 10.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +33.7 % per year. As of Oct 4, 2026.
What discount rate (WACC) does the fair value of SEMG use?
Our models discount Seach Medical Group Ltd at 10.1 %: a base by market capitalisation (nano), damped by beta 0.28, country premium for Israel. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Seach Medical Group Ltd that is -18.1 % per year a year over ten years, using the same discount rate (10.1 %) and the same formula as our fair value.
How much growth has Seach Medical Group Ltd (SEMG) delivered so far?
Over the past 5 years revenue at Seach Medical Group Ltd grew +33.7 % a year. The price currently implies -18.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Seach Medical Group Ltd (SEMG) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into Seach Medical Group Ltd (-18.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Seach Medical Group Ltd (SEMG)?
The free-cash-flow yield on the price is 16.64 %: that much free cash flow Seach Medical Group Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Seach Medical Group Ltd (SEMG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Seach Medical Group Ltd it is 2.14 ILA per share (as of Oct 4, 2026), against a price of 2.82 ILA. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Seach Medical Group Ltd stock overvalued or undervalued in 2026?
As of Oct 4, 2026, SEMG trades above its calculated fair value: price 2.82 ILA, fair value 2.14 ILA, a gap of about −24% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SEMG?
No. The price is what the market pays today (2.82 ILA); the fair value is what the company's own numbers justify (2.14 ILA). For Seach Medical Group Ltd the two are 0.6750 ILA per share apart. That gap is exactly why we show both numbers side by side.
How much is Seach Medical Group Ltd worth?
The market values Seach Medical Group Ltd at about 93.2M ILA (market capitalisation, as of Oct 4, 2026). Per share that is 2.82 ILA; our models calculate a fair value of 2.14 ILA per share.
What do the bullish and bearish scenarios say about SEMG?
Our models span a range for Seach Medical Group Ltd: cautious scenario 1.83 ILA, base 2.14 ILA, optimistic 2.78 ILA per share (as of Oct 4, 2026, price 2.82 ILA). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SEMG?
Seach Medical Group Ltd trades at a price-to-earnings ratio of 14.6 (as of Oct 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 2.14 ILA is built from several models across several years. Other multiples: P/B 1.0, P/S 0.6, EV/EBITDA 4.6.
How solid is the balance sheet of Seach Medical Group Ltd (SEMG)?
Balance-sheet figures for Seach Medical Group Ltd (as of Oct 4, 2026): return on equity 5.5%. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is SEMG from its 52-week high?
Seach Medical Group Ltd trades at 2.82 ILA, about 10% below its 52-week high of 3.14 ILA and 31% above the low of 2.15 ILA (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of 2.14 ILA is for.
Which stocks are comparable to Seach Medical Group Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Seach Medical Group Ltd stock attractive at the current price?
The data as of Oct 4, 2026: price 2.82 ILA, calculated fair value 2.14 ILA (−24%), Quality Score 64/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SEMG calculated?
We run Seach Medical Group Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 2.14 ILA, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Seach Medical Group Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Seach Medical Group Ltd (SEMG)?
The closing price on Oct 1, 2026 was 2.82 ILA. Our model-based fair value is 2.14 ILA, about −24% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Seach Medical Group Ltd right now?
Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Seach Medical Group Ltd
How large is the market capitalisation of Seach Medical Group Ltd (SEMG)?
The market capitalisation of Seach Medical Group Ltd is 93.2M ILA. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Seach Medical Group Ltd (SEMG)?
The price-to-sales ratio of Seach Medical Group Ltd is 0.14 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Seach Medical Group Ltd (SEMG)?
Earnings per share at Seach Medical Group Ltd are 0.1930 ILA (price ÷ EPS = P/E 14.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Seach Medical Group Ltd (SEMG)?
The dividend yield of Seach Medical Group Ltd is 6.4% (payout 93.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Seach Medical Group Ltd (SEMG)?
The net margin of Seach Medical Group Ltd is 1.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Seach Medical Group Ltd (SEMG)?
The return on equity (ROE) of Seach Medical Group Ltd is 5.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Seach Medical Group Ltd (SEMG)?
On an EBIT basis the return on assets of Seach Medical Group Ltd is 5.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Seach Medical Group Ltd (SEMG)?
The operating margin of Seach Medical Group Ltd is 16.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Seach Medical Group Ltd (SEMG)?
Revenue at Seach Medical Group Ltd is growing −7.3% versus a year earlier (3y avg +5.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Seach Medical Group Ltd (SEMG)?
Earnings per share at Seach Medical Group Ltd are growing +44.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Seach Medical Group Ltd (SEMG) carry?
The net debt of Seach Medical Group Ltd is 8.7M ILA (fiscal year 2025, ≈ 0.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Seach Medical Group Ltd in the live analysis
One click puts Seach Medical Group Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
